Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear. METHODS: In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus VRd or VRd alone. The primary efficacy end point was progression-free survival. Key secondary end points included a complete response or better and minimal residual disease (MRD)-negative status in patients with a complete response. RESULTS: A total of 446 patients underwent randomization. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group (hazard ratio for disease progression or death, 0.60; 98.5% confidence interval, 0.41 to 0.88; P<0.001). The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%, P = 0.01), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%, P = 0.003). No new safety signals were observed with the isatuximab-VRd regimen. The incidence of serious adverse events during treatment and the incidence of adverse events leading to discontinuation were similar in the two groups. CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, NCT03319667.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Isatuximab plus VRd (Isa-VRd) has also shown impressive results in newly diagnosed myeloma.102,103”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [102]
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
RetractedKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citation
Cited by
Items 101–200 of 283
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
Neupane, K., Singstock, M., Shah, D., Dahal, R., Mian, H. S., Smith, F., Chakraborty, R., Hadidi, S. S. A. A., Mainou, M., Grajales-Cruz, A. F., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70323 · Cited by 3
“5,42 Of note, the CEPHEUS trial excluded patients who were frail, and no enrolled patients were above the age of 80, while the IMROZ trial explicitly excluded patients age greater than 80.”
Roy, P. G., Gogia, A., Anwar, Z., Mukherjee, S., & Anwer, F. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00947 · Cited by 2
Lowy, J. A., Rogers, M. F., Avigan, Z. M., Flores, M. S., Samuel, M., Rattu, M. A., & Richter, J. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2634283 · Cited by 2
Paulson, R. S., Gautam, S., Medhekar, R., Mahmud, S., Mirsalehi, A., Ensley, L., Shelley, B., Brisbin, L., Lisi, M., Khare, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1736892 · Cited by 2
“The IMROZ trial demonstrated the increased ef fi cacy of isatuximab-VRd compared to VRd for 1L treatment of NDMM (15).”
Chari, A., Costello, C. L., Krishnan, A. Y., Patel, K. K., Banerjee, R. K., Berdeja, J. G., Biran, N., Callander, N. S., Costa, L. J., Dhakal, B., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70339 · Cited by 4
“In the CEPHEUS trial of daratumumab plus VRd and the IMROZ trial of isatux-imab plus VRd, both intended for transplant-ineligible patients, bortezomib was administered twice weekly for 6 months and no proteasome inhibitor was administered thereafter [16, 17].”
Lemieux, M., Chunara, F., Szabó, A., Oekelen, O. V., Chakraborty, R., Godara, A., Shaikh, H. G., Strouse, C. S., Mohan, M., & Mohyuddin, G. R. (2026) · American Journal of Hematology · doi:10.1002/ajh.70349 · Cited by 2
Liang, D., Bai, S., Feng, D., Chen, G., Liang, Y., & Wang, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-12880-9 · Cited by 2
“In our study, non-transplants who received VRD treatment had a three-year OS of 88% and a three-year PFS of 71% [25].”
BackgroundOverview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts
D’Agostino, M., Martello, M., Paoli, L. D., Mangiacavalli, S., Derudas, D., Fazio, F., Furlan, A., Liberatore, C., Mele, G., Mina, R., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06212-5 · Cited by 4
Self-citationChari, A., Bal, S., Ailawadhi, S., Krishnan, A. Y., Patel, K. K., Berdeja, J. G., Garfall, A. L., Callander, N. S., Banerjee, R., Alsina, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.008 · Cited by 4
Updates to Management of Multiple Myeloma
Callander, N. S., Mangan, P. A., & Kumar, S. K. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.5008 · Cited by 4
Ntanasis‐Stathopoulos, I., Malandrakis, P., Filippatos, C., Maganas, S., Fotiou, D., Theodorakakou, F., Spiliopoulou, V., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.003 · Cited by 3
Self-citationWang, C., Xu, Z., Jiang, M., Chen, Y., & Yu, L. (2025) · Cancers · doi:10.3390/cancers17203349 · Cited by 2
“It is noteworthy that isatuximab, another anti-CD38 monoclonal antibody, has also demonstrated significant efficacy in TIE NDMM, as evidenced by the IMROZ trial [12].”
Emerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Hill, E., & Kazandjian, D. G. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.02.002 · Cited by 3
Isatuximab for Stem Cell Transplant-Ineligible Multiple Myeloma: An Editorial
Hasan, A. H., Abid, M. A., & Tariq, B. (2024) · Cureus · doi:10.7759/cureus.72177 · Cited by 2
Diamond, B. T., Baughn, L. B., Poorebrahim, M., Poos, A. M., Lee, H., Kaddoura, M., Wiedmeier, J. E., Durante, M. A., Otteson, G. E., Jevremović, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.628799 · Cited by 2
Matsumura, N., & Mandai, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02741-1 · Cited by 2
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma
Chakraborty, R., & Mian, H. S. (2024) · American Journal of Hematology · doi:10.1002/ajh.27473 · Cited by 1
“6,7 The IMROZ phase III trial evaluated the CD38mAb isatuximab on the backbone of bortezo-mib, lenalidomide, and dexamethasone (Isa-VRd) compared with VRd alone.”
InfluentialPasvolsky, O., Marcoux, C., Wang, Z., Milton, D. R., Pal, B., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.12.023 · Cited by 2
Self-citationBlurring the Lines: Beyond Using Transplant Eligibility to Guide Induction Therapy in Myeloma
Pan, D., Kumar, A. D., Chung, A., & Chari, A. (2025) · The Hematologist · doi:10.1182/hem.v22.1.202524 · Cited by 1
Liang, T. B., Yan, L., Li, J., Gai, D., & Xu, C. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2499218 · Cited by 2
Zhou, H., & Chen, W.-M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1575914 · Cited by 1
Martins, K. A. M., Cardoso, L. J. C., Ribeiro, F. M., Pereira, A. L., Gontijo, P. H. G., Oliveira, J., Danielian, P. L. L. B., Américo, A. D., & Scheinberg, P. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.007 · Cited by 2
New therapeutic options and trends in the treatment of multiple myelom
Hájek, R., Muroňová, L., Mihályová, J., Horňáková, M., Popková, T., Plonková, H., & Jelínek, T. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.031 · Cited by 1
Self-citationThe challenge of non-transplant eligible, newly diagnosed multiple myeloma
Ntanasis‐Stathopoulos, I., Solia, E., Filippatos, C., Gavriatopoulou, M., & Terpos, E. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2513676 · Cited by 1
“…of daratumumab with lenalido-mide and dexamethasone (Dara-Rd), daratumumab with bortezomib, melphalan and prednisone (Dara-vMP), and vRd [11,13,14,16,20,21,52]. therefore, the availability of several different choices will necessitate a tailored and individualized approach. it should be…”
New prognostic systems for multiple myeloma in the context of contemporary therapies
Spencer, A. G. (2025) · Blood · doi:10.1182/blood.2024023841 · Cited by 2
Bringhen, S., Cani, L., Giuliani, N., Mangiacavalli, S., Benevolo, G., Antonioli, E., Zambello, R., Ria, R., Vincelli, I. D., Ronconi, S., et al. (2025) · Haematologica · doi:10.3324/haematol.2025.287510 · Cited by 1
“9,11,12 Nonetheless, the optimal schedule for bortezomib remains unclear, as it was administered twice weekly in the IMROZ trial and once weekly – but for a longer duration – in the BENEFIT trial.”
Rees, M. J., & Quach, H. (2025) · Cancers · doi:10.3390/cancers17152579 · Cited by 1
“%) and both met their PFS primary endpoints [37,38].”
Raddoux, J., Kenis, C., Vanhellemont, A., Meers, S., Mineur, P., Vekemans, M., Wu, K. L., Caers, J., Eygen, K. V., Kentos, A., et al. (2025) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2025.102329 · Cited by 1
Zhao, S., Wellard, C. J., Moore, E., Spencer, A. G., Quach, H., Ho, P. J., McDonald, E.-J., Mollee, P. N., Harrison, S. J., Augustson, B. M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.004 · Cited by 1
Systchenko, T., Nsiala, L., Bobin, A., Gardeney, H., Motard, C., Olivier, G., Borde, F., Corby, A., Roul, C., Fleck, E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016625 · Cited by 1
Self-citationVisram, A., Mian, H. S., Lee, J., Jones, A., Pond, G. R., Hansen, D. K., Sidana, S., & Costa, L. J. (2025) · British Journal of Haematology · doi:10.1016/s2152-2650(25)03424-x · Cited by 2
Doshi, A., Filho, J. T. D. S., Grimshaw, A. A., Giri, S., & Costa, L. J. (2025) · British Journal of Haematology · doi:10.1111/bjh.70199 · Cited by 1
Current Status of Molecularly Targeted Therapeutics in Blood Cancers
Kumala, C., Vu, L., & Fandy, T. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110512 · Cited by 1
Wang, C., Xu, Z., Jiang, M., Chen, Y., & Lan, Y. (2025) · Cancers · doi:10.3390/cancers17213494 · Cited by 1
Identification and transformation of novel targets for immunotherapy in multiple myeloma
Wang, Y., Wang, Y., Ma, J., Jing, H., Liu, L., Qiu, L., & Hao, M. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003869 · Cited by 2
“…administered in combination with lenalidomide, dexamethasone, and bortezomib, has led to clinical improvements in both transplant-eligible and trans-plant-ineligible patients diagnosed with NDMM. [68,69] However, few studies have directly compared the clinical effects of daratumumab and isatuximab.”
Park, S., Kim, E.-S., Youn, J., Jung, M., Park, J., Nam, K. E., Min, C., Armenian, S. H., & Lee, K. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01719-6 · Cited by 2
“For instance, clinical trials involving newly diagnosed MM patients report that severe (grade ≥ 3) neutropenia occurs in 30–60% of patients, thrombocytopenia in 10–30%, and anemia in 10–20% [ 22, 23 ].”
Guadagno, L., Schütt, J., Brinkert, K., Schenk, T., & Brioli, A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2575438 · Cited by 3
“…role in defining the subclonal architecture and the tumor progression [5]. treatment of MM has undergone a profound change in the last two decades [6–14], translating in an increased progression free and overall survival for MM patients with an estimated progression free survival for patients…”
High Implementation Adherence to Lenalidomide in Multiple Myeloma
Amitai, I., Magen, H., Leader, A., Pironet, A., Tousset, E., Rozental, A., Geest, S. D., Vaxman, I., Raanani, P., & Nagler, A. (2025) · Cancers · doi:10.3390/cancers17213587 · Cited by 1
Sáez, A., Hernandez-Ibarbu, G., de Alba, L. M., Babio, R. M., Tamayo, A., Fonseca, A. C., Sánchez‐Pina, J. M., Fernández, R. A. A., López‐Muñoz, N., Sánchez, A. B., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.021 · Cited by 1
Iriyama, N., Nakayama, H., Nakagawa, M., Takahata, A., Sato, E., Takano, M., Okada, K., Toyama, K., Hayashi, T., Abe, T., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04100-2 · Cited by 1
Jimenez-Zepeda, V. H., Cheung, W. Y., Stephen, M. M., & Chan, H. S. H. (2025) · Future Oncology · doi:10.1080/14796694.2025.2589058 · Cited by 1
Lin, J., He, J., Cai, Z., & He, D. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2596804 · Cited by 1
“Furthermore, the phase 3 PeRSeUS trial [15], the BeNeFit trial [16], the iskia trial [17] and the iMROZ trial [18] collectively demonstrated that patients achieving higher rates of MRD negativity have a strong positive correlation with significantly prolonged overall survival.”
What is the best induction for myeloma for the fit patient?
Shah, N. N., & Kaufman, J. L. (2025) · Hematology · doi:10.1182/hematology.2025000731 · Cited by 1
How to approach the high-risk myeloma from induction through relapse?
Weisel, K. C., Schaefers, C., & Leypoldt, L. B. (2025) · Hematology · doi:10.1182/hematology.2025000762 · Cited by 1
Pasvolsky, O., Marcoux, C., Milton, D. R., Haider, A. A., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Smallbone, P., Lin, P., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02771-3 · Cited by 3
Self-citationLiu, Y., Zhang, Y., Yang, W., Du, H., Sun, S., Li, Z., & Zong, D. (2025) · Pharmaceuticals · doi:10.3390/ph19010018 · Cited by 1
First-line Therapy in Newly Diagnosed Multiple Myeloma
Miller, K. C., & Usmani, S. Z. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0384 · Cited by 2
Feng, A., Wu, J., Choi, T., Wang, X., Bellavia, T., Burcher, K. M., Jones, L., Schrum, D. P., Eberwein, E., Cheng, S., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.02.009 · Cited by 1
Smith, E., Camera, A., & Bird, A. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00419-w · Cited by 1
“Regimen-specific dosing schedules were calculated on the basis of approved treatment regimens and published literature [9, 16–18], with the assumption that there are 104 weeks in a 2-year period.”
InfluentialZhou, X., Liu, Y., Zhang, P., & Shan, N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178812 · Cited by 1
Liu, J., Fan, X., Peng, L., Liu, J., He, H., Qiang, W., Jin, L., Shi, L., Lu, J., Guo, P., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019036 · Cited by 2
“40,43,44,51,52 In this study, after AZD0120 CAR T-cell infusion, 2 patients with an ECOG performance status score of 2 recovered to an ECOG performance status score of 1.”
Derman, B. A., Essell, J. H., Ascha, M. S., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Neiman, J., Travis, P. M., Schaefer, E. S., Hunnicutt, J., et al. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01188 · Cited by 1
Ocio, E. M., Parmar, G., Mateos, M., Leleu, X. P., Buck, T. T., Tan, C. R., Curry, N. C., Ling, S., Quach, H., Mai, E. K., et al. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2659263 · Cited by 2
Self-citationChen, W., Cai, Z., Chim, C. S., Chng, W. J., Du, J., Fu, C., Gao, W., Hanamura, I., Hou, J., Huang, J. S.-Y., et al. (2026) · Clinical Hematology International · doi:10.46989/001c.160933 · Cited by 2
Self-citationWesley, E., Anwer, F., Rothberg, M. B., Kovach, J. D., Casacchia, N. J., Peterre, B., Wang, M., Raza, S., Williams, L. S., Valent, J. N., et al. (2026) · eJHaem · doi:10.1002/jha2.70309 · Cited by 1
Zhong, D., Cheng, H., zeng, L., Tian, C., Liang, C., Wei, H., Xu, M., Pang, M., Ke, Q., Tan, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1869797 · Cited by 1
Peck, O. H., McCoubrey, A., Snowden, J. A., Wechalekar, A. D., Travers, J., Lees, J. S., Petrie, M. C., & Lang, N. N. (2026) · Open Heart · doi:10.1136/openhrt-2026-004240 · Cited by 1
(2024) · EMJ Hematology · doi:10.33590/emjhematol/umdh9964 · Cited by 1
“5,6 In particular, Beksac highlighted the low discontinuation rate due to AEs among the IMROZ population (22.8% with Isa-VRd versus 26.0% with VRd) as further evidence of the quadruplet’s favourable safety profile.”
InfluentialActualités 2024 par le Comité de rédaction du Bulletin du cancer : congrès ASCO, ESMO et au-delà
Vignot, S., Bellesœur, A., Bouleuc, C., Cohen, R., Courtier, B., Crozier, C., de Nonneville, A. T., Delom, F., Évrard, S., Firmin, N., et al. (2024) · Bulletin du Cancer · doi:10.1016/j.bulcan.2024.12.001 · Cited by 1
ANALYSIS OF THE EFFECTIVENESS OF BORTEZOMIB-CONTAINING REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA
Stadnik, Y. O., & Maslova, H. S. (2024) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.24.4.72 · Cited by 1
“Отримані дані узгоджуються з резуль-татами інших досліджень, що підтверджує ефек-тивність застосування схеми VRD як терапії І лі-нії у пацієнтів з вперше діагностованою ММ [1, 4, 6, 9, 10, 18].”
McLoughlin, A., & Rees, M. J. (2025) · Lymphatics · doi:10.3390/lymphatics3020014 · Cited by 1
Landgren, O., Biran, N., O’Donnell, E., Mikhael, J. R., Weisel, K. C., Broijl, A., Usmani, S. Z., Moreau, P., Gay, F., Mina, R., et al. (2025) · HemaSphere · doi:10.1002/hem3.70178 · Cited by 1
Self-citationAktuelle Fortschritte und neue Therapieoptionen in der Immunonkologie
Kobold, S., & Müller, R. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2502-1305 · Cited by 1
Isatuximab-Based Therapy for Multiple Myeloma
Sampath, V. S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2414957 · Cited by 1
Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma
Richardson, P. G. G., Munshi, N. C., & Longo, D. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2507131 · Cited by 3
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM
Killock, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00918-7
Isatuximab plus carfilzomib–dexamethasone for relapsed multiple myeloma
Maruyama, D., & Yamauchi, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00220-5
Risk‐adapted treatment in multiple myeloma: Does more make it merrier?
Zanwar, S., Fortuna, G. G., & Sborov, D. W. (2024) · British Journal of Haematology · doi:10.1111/bjh.19676
“3,4 However, only a small proportion of the patients enrolled in these studies harboured high-risk features and patients with HRMM are yet to see the same gains in survival outcomes that have been such a success story for patients with standard risk disease.”
Wei, X., Wang, Y., Zhang, L., Dong, H., Chen, H., Zhang, H., Yuan, Y., Zhang, C., Feng, R., & Wei, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-5411786/v1
Immuntherapien des multiplen Myeloms
Kadel, S., & Rasche, L. (2025) · Die Onkologie · doi:10.1007/s00761-024-01658-0
Phua, C. W. T., & McCulloch, S. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4s0161
Myélome multiple : ce que le rhumatologue doit savoir en 2025
Belkhir, R. (2025) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.01.022
Optimising quadruplet regimens to broaden eligibility in multiple myeloma
Wildes, T. M. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00356-9
Systchenko, T., Nsiala, L., Bobin, A., Gardeney, H., Motard, C., Olivier, G., Borde, F., Corby, A., Roul, C., Fleck, E., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5112748
Self-citationTherapie des multiplen Myeloms – was ist neu und was bleibt?
Kortüm, K. M., Waldschmidt, J. M., & Einsele, H. (2025) · Die Onkologie · doi:10.1007/s00761-024-01675-z
Soloveva, M. V., Solovev, M. V., Kovrigina, A. M., & Менделеева, Л. П. (2025) · Journal of Modern Oncology · doi:10.26442/18151434.2024.4.203086
Daratumumab for high-risk smoldering multiple myeloma – Are we there yet?
Lal, B. M., & Hadidi, S. A. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115391 · Cited by 1
Hilfe bei der Wahl der bestmöglichen Erstlinientherapie
Mertens, L., Hentrich, M., & Högner, M. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0955-4
Pianko, M. J., Gupta‐Werner, N., Émond, B., Lefèbvre, P., Lafeuille, M.-H., Cortoos, A., & Kaila, S. (2025) · Future Science OA · doi:10.1080/20565623.2025.2528523
“…current evidence shows that triplet regimens can also be efficacious among these patients, and quadruplets are under study in this population [32,33]. specifically, in a trial of 525 frontline NDMM patients without intent for immediate asct on triplet therapy, PFs improved in all three of the…”
Gupta‐Werner, N., Khare, V., Macomson, B., & Medhekar, R. (2025) · Journal of health economics and outcomes research · doi:10.36469/jheor.2025.141714
Chalopin, T., Decaux, O., Hulin, C., Perrot, A., Macro, M., Royer, B., Bastie, J.-N., Bobin, A., Jacquet, C., Mohty, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.07.009
Self-citationGupta‐Werner, N., Khare, V., Macomson, B., & Medhekar, R. (2025) · Journal of health economics and outcomes research · doi:10.36469/jheor.2025.143106
Gupta‐Werner, N., Khare, V., Macomson, B., & Medhekar, R. (2025) · Journal of health economics and outcomes research · doi:10.36469/001c.143106
Novellis, D. D., Palmieri, S., Rocco, S., Derudas, D., Pepa, R. D., Roccotelli, D., Esposito, D., Masucci, C., Gigliotta, E., Barone, M. L., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06572-y
“…both ASCT-eligible and ineligible patients could maximize efficacy, reducing the risk of developing FHRMM and thus improving overall patient outcomes [27– 29 ]; however, the presence of lenalidomide in these combi - nations could not allow to use this drug as salvage therapy in refractory patients.”
Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Bhutani, D., Liu, Y. K., Chakraborty, R., Hughes, M. S., Lentzsch, S., & Rubinstein, S. M. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.04.016
Perspectives on Newly Diagnosed Myeloma Treatment and Emerging Challenges
Touzeau, C., & Moreau, P. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0280
Self-citationMerz, M. (2025) · Blood · doi:10.1182/blood.2025029889
Mel, S. D., Tso, A. C. Y., Soekojo, C. Y., Ooi, M. G. M., Lim, C. C., Teo, C., Chen, Y. X., Tan, M. S. Y., Manjeri, A., Lee, Z. Y., et al. (2025) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202532 · Cited by 1
Czernilofsky, F., & Raab, M. S. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.1
Multiples Myelom: Hochrisikomyelom Therapiestrategien und neue Ansätze
Artzenroth, C., Al-Bazaz, M., Kosch, R., Schaefers, C., Weisel, K. C., & Leypoldt, L. B. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.2
More is not always more for older patients with multiple myeloma
Shain, K. H. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00357-2
Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management
Yasar, F. Z., & Gorshein, E. (2025) · Advances in Hematology · doi:10.1155/ah/6622365 · Cited by 1
“Tis suggests that high-risk transplant-ineligible patients may require alternative in-tensifcation strategies beyond anti-CD38 addition [44].”
Suzuki, K., Gunji, T., Nagao, R., Uryu, H., Watanabe, K., Yokoyama, H., Katsube, A., Ishii, H., Nakano, A., Hattori, D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7547993/v1
Belantamab mafodotin for the treatment of multiple myeloma
Oriol, A., Ibarra, G., Loscos, J., & Abril, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2576502
Assumptions Matter: The Long-Term Cost Analysis of IsaVRd vs DVRd
Feng, L., Petitjean, A., & Susan, M. (2025) · Journal of health economics and outcomes research · doi:10.36469/jheor.2025.145075
Assumptions Matter: The Long-Term Cost Analysis of IsaVRd vs DVRd
Lin, F., Petitjean, A., & Sasané, M. (2025) · Journal of health economics and outcomes research · doi:10.36469/001c.145075
Ahlstrom, J., & Costa, L. J. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00389-5
“But now we have two large trials, with one called CEPHEUS with DARA-VRd [11] and the other called IMROZ with isatuximab-VRd [12].”
Mainou, M., Alsadhan, M., Tsapa, K., Visram, A., Mian, H. S., Popat, R., Mai, E. K., Chakraborty, R., Hadidi, S. A., Mohan, M., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf326
Isatuximab: surface strike, deep response in AL amyloidosis
Muchtar, E., & Dispenzieri, A. A. (2025) · Blood · doi:10.1182/blood.2025031062
Metadata
- Authors
- Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., Spicka, I., Vorobyev, V. I., Besemer, B., Ishida, T., Janowski, W., Kalayoglu-Besisik, S., Parmar, G., Robak, P., Zamagni, E., Goldschmidt, H., Martin, T. G., Manier, S., Mohty, M., Oprea, C., Brégeault, M.-F., Macé, S., Berthou, C., Bregman, D., Klippel, Z., & Orlowski, R. Z.
- Affiliations
- Inserm (FR)
- From the Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research and Development, Vitry-sur-Seine (C.O., M.-F.B., S. Macé, C.B.) — all in France; the Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens (M.-A.D.); the Department of Hematology, Ankara University, and the Istinye University Ankara Liv Hospital, Ankara (M.B.), and the Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul (S.K.-B.) — all in Turkey; the Department of Internal Medicine, Hematology, and Oncology, Uni...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1597-1609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399304831
- Semantic Scholar
- a45e6cd60318735bf0f85aba849da20117440058
- Cited by
- 284
- References
- 30
- Citations by year
- 2026: 100 · 2025: 155 · 2024: 29
- FWCI
- 87.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- isatuximab, bortezomib, lenalidomide, dexamethasone, multiple myeloma, newly diagnosed multiple myeloma, anti-CD38 monoclonal antibody, progression-free survival, complete response, minimal residual disease, transplant-ineligible patients, first-line therapy
- MeSH terms
- Bortezomib, Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.